The endoscopy is standard. The biopsy protocol carries the weight.
The procedure itself is an ordinary upper endoscopy (EGD, a scope passed down the throat to examine the esophagus, stomach, and upper small intestine). The same scope and basic procedure are used for many gastrointestinal problems.
What makes an endoscopy useful for evaluating autoimmune atrophic gastritis (damage to the stomach lining caused by the immune system attacking its own cells) and gastric cancer risk is how the stomach is examined and biopsied.
A doctor can perform an EGD, look around the stomach, take one or two biopsies, and still fail to establish the information needed to assess the extent of atrophic gastritis. A visually normal-looking stomach can still carry significant microscopic damage. The biopsies are what reveal it, not the visual exam.
Gastric mapping
The stomach needs to be sampled systematically so the pathologist can determine where the damage is and how extensive it is.
The updated Sydney protocol uses five mapped biopsies:
- Two from the antrum (the lower part of the stomach)
- Two from the corpus (the main body of the stomach)
- One from the incisura angularis (the bend where the antrum meets the corpus)
Any visually abnormal area gets biopsied separately, in addition to these five.
The important point for a patient is simple: random gastric biopsies are not equivalent to systematic gastric mapping. A doctor who takes two samples from wherever looks convenient has not performed the same exam as a doctor who takes five samples from these specific locations.
The baseline’s purpose
Pernicious anemia is a late manifestation of autoimmune gastritis in many patients. By the time pernicious anemia develops, substantial loss of acid-producing parietal cells (the stomach cells that also produce the protein needed to absorb B12) may already have occurred.
Autoimmune atrophic gastritis increases the risk of both gastric adenocarcinoma and type 1 gastric neuroendocrine tumors (NETs, small growths that arise from hormone-producing stomach cells).
A properly performed initial endoscopy establishes:
- Where atrophy is present
- How extensive and severe it is
- Whether intestinal metaplasia is present (a change in the stomach lining’s cell type, itself a precancerous marker)
- Whether dysplasia or cancer is present
- Whether a gastric neuroendocrine tumor is present
- Whether H. pylori is present
This baseline determines a patient’s future gastric cancer risk and need for ongoing surveillance. Without it, there is nothing to compare later findings against.
Risk factors
Autoimmune gastritis and pernicious anemia are part of a larger gastric cancer risk picture. A patient can land in the surveillance conversation through any of the following, alone or in combination:
Tissue-level findings, regardless of what triggered the scope:
- Extensive atrophic gastritis or intestinal metaplasia, particularly when it involves both the antrum and corpus rather than one location, when it’s the higher-risk “incomplete” subtype under the microscope, or when it stages at OLGA/OLGIM III or IV (a staging system pathologists use to grade the extent of damage)
- Persistent H. pylori infection that hasn’t been treated
History and demographics:
- First-degree family history of gastric cancer (a parent, sibling, or child)
- First-generation immigration from a region with high gastric cancer incidence
- Age over 50
- Smoking history
- A prior partial gastrectomy (surgical removal of part of the stomach)
Hereditary syndromes, a separate tier driven by inherited genetic mutations rather than autoimmune disease:
- Hereditary diffuse gastric cancer, caused by a CDH1 gene mutation. This carries risk aggressive enough that family members of a confirmed carrier are placed on a tighter one-year surveillance interval, not the standard interval used for atrophic gastritis
- Lynch syndrome, familial adenomatous polyposis, and other hereditary GI cancer syndromes
Pernicious anemia feeds into the tissue-level findings category. It’s one route to the atrophic gastritis finding that opens the surveillance conversation, not the only one. A patient can arrive at the same risk category through H. pylori alone, family history alone, or a hereditary syndrome, with no autoimmune involvement at all.
H. pylori is truthable
Every other item on this list describes a risk a patient carries or a finding a biopsy reveals. H. pylori is different: it’s an infection, and it’s treatable.
If gastric biopsies come back positive for H. pylori, eradicating it is the first move, ahead of anything else. Every major guideline on this topic treats H. pylori eradication as the primary modifiable intervention for reducing gastric cancer risk. Clearing the infection doesn’t reverse existing atrophic damage, but it removes an active driver of further damage, and it changes a patient’s risk trajectory going forward.
This makes the H. pylori test on the initial biopsy panel one of the most consequential results on the report. A positive result has a clear next step. Most of the other findings only inform surveillance timing.
Pathology determines the next step
A pathology report that simply says “gastritis” or “normal biopsies” doesn’t answer the question a patient actually needs answered. The report should describe the location and severity of atrophy and intestinal metaplasia, note relevant findings such as dysplasia or H. pylori, and ideally include OLGA or OLGIM staging.
Advanced disease, meaning extensive involvement of both the antrum and corpus, or an OLGA/OLGIM stage of III or IV, generally places a patient in a higher-risk group. Guidelines commonly recommend a surveillance endoscopy every three years for this group, though the exact interval is still debated and should reflect individual circumstances and a discussion between patient and doctor.
Limited, mild disease can carry a substantially lighter surveillance recommendation, sometimes none at all beyond routine care.
If the initial endoscopy identifies a gastric neuroendocrine tumor, small tumors are typically removed endoscopically during the same or a follow-up procedure, and the patient moves to a tighter one to two year surveillance interval rather than the standard three-year interval, reflecting the higher rate of new tumor formation in this group.
The question that actually matters
A patient can have several previous endoscopies and still never have had an adequate baseline evaluation for autoimmune atrophic gastritis.
The useful question isn’t:
“Have I had an endoscopy?”
It’s:
“Have I had a high-quality EGD with systematic gastric mapping biopsies, sufficient to determine the location and extent of atrophy and intestinal metaplasia?”
For a patient with pernicious anemia or suspected autoimmune gastritis, or anyone else who falls into the risk categories above, that distinction is the difference between an exam that establishes real information and one that technically happened without answering anything.
Documenting the request
A verbal conversation with a doctor about biopsy protocol leaves no record. If the biopsies don’t get taken correctly, or the request needs to be raised with a different provider, insurance, or a second opinion later, there’s nothing to point back to.
Putting the request in writing, ahead of the procedure date, through a letter or a patient portal message, creates a timestamped record that the specific request was made. The template below can be copied, filled in with a patient’s own information and specific risk factor, and sent to a provider before the scheduled date.
Upper Endoscopy Procedure Specifications
Patient: [Your name]
Date of Birth: [Your date of birth]
Scheduled Procedure: Upper endoscopy (EGD), [date]
Endoscopist: [Name, practice]
Referring Provider: [Name, credentials, practice]
I’m writing to confirm the specific biopsy protocol for my upcoming EGD, so this can be documented ahead of the procedure date.
Indication
[State your specific reason for gastric cancer surveillance — for example: autoimmune gastritis/confirmed pernicious anemia, persistent H. pylori infection, first-degree family history of gastric cancer, a prior finding of atrophic gastritis or intestinal metaplasia, or a hereditary gastric cancer syndrome.]
Requested biopsy protocol
Gastric biopsies — per updated Sydney System protocol for atrophic gastritis and intestinal metaplasia surveillance:
- Two biopsies from the antrum
- Two biopsies from the corpus
- One biopsy from the incisura angularis
- Each site labeled and submitted separately, not pooled into a single specimen
H. pylori testing — to be performed on the gastric biopsy tissue.
Additional request
If any mucosal abnormality is identified during the procedure, including discoloration, coating, lesions, or other visible findings, please photograph and document the finding in the procedure report.
Thank you for your attention to these details ahead of the procedure.
[Your name]
[Your phone number]
Key live references
- ACG Clinical Guideline: Diagnosis and Management of Gastric Premalignant Conditions (2025): https://journals.lww.com/ajg/fulltext/9900/acg_clinical_guideline__diagnosis_and_management.1623.aspx
- AGA Clinical Practice Update on Screening and Surveillance in Individuals at Increased Risk for Gastric Cancer (2025): https://www.gastrojournal.org/article/S0016-5085(24)05663-4/fulltext
- ESGE/EHMSG/ESP MAPS III Guideline update (2025): https://www.esge.com/management-of-epithelial-precancerous-conditions-and-early-neoplasia-of-the-stomach-maps-iii-esge-ehmsg-esp-guideline-update-2025
- Updated Sydney System original description (Dixon et al., 1996): referenced across guidelines; summary available in quality-indicator literature such as https://www.giejournal.org/article/S0016-5107(24)03460-6/fulltextDixon MF, Genta RM, Yardley JH, Correa P. “Classification and grading of gastritis. The updated Sydney System.” Am J Surg Pathol. 1996;20(10):1161-1181: https://pubmed.ncbi.nlm.nih.gov/8827022/
- Real-world evidence that routine Sydney protocol improves detection of advanced stages: https://www.sciencedirect.com/science/article/pii/S244438242400110X